|
**Overview**: Hepatitis C Viral Combo Panel**Introduction**: The Hepatitis C Viral Combo Panel is a diagnostic tool designed for comprehensive HCV screening using serum samples. In India, chronic hepatitis C affects ~12-18 million people (~1 percent prevalence), with high transmission through unsafe injections, blood transfusions, and intravenous drug use, leading to cirrhosis and hepatocellular carcinoma in 20-30 percent of chronic cases over 20-30 years. High morbidity from under-testing in rural/low-SES populations with risk factors, limited labs, delayed direct-acting antiviral (DAA) therapy leading to advanced liver disease or HCC. Per microbiology practices aligned with ICMR and National Viral Hepatitis Control Programme guidelines, the test employs immunoassay for HCV antibody and qualitative RNA over 1-2 days with high accuracy, valuable for initial screening and confirmation of active infection. This diagnostic falls under viral screening and targets high-risk individuals (blood recipients pre-2002, IVDU, hemodialysis patients), addressing accurate detection to guide DAA therapy (sofosbuvir-based regimens) and monitoring. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing HCV-related mortality. Its serum-based approach ensures reliable serology and RNA detection.**Other Names**: Hep C Combo Pnl.**FDA Status**: FDA approved, CLIA certified for microbiology/oncology, compliant with 2025 standards.**Historical Milestone**: HCV combo screening standard; in India, scaled under NVHCP.**Purpose**: The test assesses 2 parameters including HCV antibody to guide comprehensive hepatitis C screening, detect exposure/active infection, inform DAA therapy.**Test Parameters**: 1. HCV Antibody, 2. HCV RNA Qualitative.**Pretest Condition**: No fasting required; patients should have risk factors or liver symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on risk factors (transfusion, tattoos, IVDU), jaundice, fatigue.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated HCV including cirrhosis/HCC, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay/PCR by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or window period can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive antibody + RNA indicates active HCV, necessitating specialist input. Antibody positive/RNA negative suggests resolved infection.**Specialist Consultation**: Hepatologists should be consulted for management.**Additional Supporting Tests**: HCV RNA quantitative, genotype for confirmation.**Test Limitations**: Qualitative RNA only; comprehensive approach required.**References**: Indian Journal of Medical Microbiology 2024, HCV Studies India 2023. |
